hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06292221 id: H19-078 id: R01MH119678 type: NIH link: https://reporter.nih.gov/quickSearch/R01MH119678 briefTitle: Personalized Depression Treatment Supported by Mobile Sensor Analytics acronym: DepWatch overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-04 date: 2025-06 date: 2024-03-05 date: 2024-03-05 name: UConn Health class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The current best practice guidelines for treating depression call for close monitoring of patients, and periodically adjusting treatment as needed. This present study seeks to develop and investigate an innovative digital system, DepWatch, that leverages mobile health technologies and machine learning tools to provide clinicians objective, accurate, and timely assessment of depression symptoms to assist with their clinical decision making process. Specifically, DepWatch collects sensory data passively from smartphones and wristbands, without any user interaction, and uses simple user-friendly interfaces to collect ecological momentary assessments (EMA), medication adherence and safety related data from patients. The collected data will be fed to machine learning models to be developed in the project to provide weekly assessment of patient symptom levels and predict the trajectory of treatment response over time. The assessment and prediction results are then presented using a graphic interface to clinicians to help them make critical treatment decisions. The main question the present clinical trial aims to answer are as follows:
2. Effectiveness of the digital tool, DepWatch, to improve depression treatment outcomes All study participants will carry the DepWatch app on their smartphones and wear a Fitbit provided by the study team during the study period. They will also complete brief questionnaires via the app at specific time intervals throughout the study period. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups of participants (64 per group) will be enrolled and will participate in the study over a 3 month period . Both will receive standard of care depression treatment with their respective providers in the clinic. Both groups will undergo standard depression assessment using depression questionnaires as well as behavioral assessments using a mobile health (mHealth) tool 'DepWatch' developed by the study team in the phase I of the study. Study clinicians will receive weekly behavioral assessment reports for participants enrolled in the first 'experimental' group and will not receive such reports for the second 'control' group primaryPurpose: DIAGNOSTIC masking: NONE maskingDescription: There is no masking count: 128 type: ESTIMATED name: A mobile Health (mHealth) tool called 'DepWatch' measure: Feasibility and Usability measure: Depression outcomes sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06292208 id: IBD0333-101 briefTitle: A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors overallStatus: NOT_YET_RECRUITING date: 2024-03-02 date: 2029-12-31 date: 2030-12-31 date: 2024-03-05 date: 2024-03-05 name: SUNHO（China）BioPharmaceutical CO., Ltd. class: INDUSTRY briefSummary: Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD), extended recommended dose (DRDE), and/or dose limiting toxicity (DLT).
Secondary objectives Dose escalation phase \& Dose expansion phase To evaluate the pharmacokinetic (PK) of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma; To evaluate the immunogenicity of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma; To evaluate the preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma.
Clinical exploration Phase To evaluate the safety and tolerability of IBD0333 in patients with specific tumor; To evaluate the immunogenicity of IBD0333 in patients with specific tumor. Exploratory Objectives To explore biomarkers in blood and tissue that predict potential efficacy of IBD0333. conditions: MTD studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: IBD0333 measure: MTD measure: DRDE measure: Dose limiting toxicity (DLT) measure: RP2D measure: ORR measure: pharmacokinetic parameters measure: pharmacokinetic parameters measure: pharmacokinetic parameters measure: pharmacokinetic parameters measure: ADA measure: ORR measure: DCR measure: DoR measure: PFS measure: Frequency of adverse events (AEs) and SAEs sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06292195 id: VitDTracking briefTitle: Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome acronym: VitDTracking overallStatus: RECRUITING date: 2023-11-03 date: 2024-12-31 date: 2025-12-31 date: 2024-03-05 date: 2024-03-05 name: University of Évora class: OTHER name: Comprehensive Health Research Centre name: Unidade Local De Saúde Do Norte Alentejano name: Unidade local de Saúde do Baixo Alentejano name: Unidade Local de Saúde do Alentejo Central name: Universidade Nova de Lisboa name: Instituto de Engenharia de Sistemas e Computadores - Inovação e Desenvolvimento de Lisboa (INESC-ID) briefSummary: The VitDTracking study focuses on the relevance of maternal vitamin D levels and their association with prematurity, aiming to improve maternal and child health outcomes, particularly by reducing avoidable preterm births. In Portugal, vitamin D levels during pregnancy have never been studied. Epidemiological data from other countries reveal a high prevalence of vitamin D deficiency/insufficiency, especially in pregnant women.
nctId: NCT06292182 id: 160802 id: 332942 type: OTHER domain: IRAS id: 58964 type: OTHER domain: CPMS briefTitle: Red Light Ptosis Proof-of-Concept overallStatus: RECRUITING date: 2024-02-08 date: 2025-11-30 date: 2025-11-30 date: 2024-03-05 date: 2024-03-05 name: University College, London class: OTHER name: Moorfields Eye Hospital NHS Foundation Trust briefSummary: This study tests a new treatment to help with droopy eyelids (ptosis) and eye movement problems (squint) in children and young people with genetically confirmed mitochondrial conditions - using red-light.
We believe that this treatment could help strengthen the muscle in the eyelid to make it easier to open the eyes, and could also help some children with squint. conditions: Mitochondrial Diseases conditions: Blepharoptosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Near-infrared light measure: Palpebral fissure width sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Moorfields Eye Hospital NHS Foundation Trust status: RECRUITING city: London zip: EC1V 2PD country: United Kingdom name: Annegret H Dahlmann-Noor, PhD role: CONTACT phone: 020 7253 3411 email: annegret.dahlmann-noor@nhs.net lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06292169 id: STUDY00007201 briefTitle: Pectoralis Minor Release Versus Non-release in RSA overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-01 date: 2026-01 date: 2024-03-05 date: 2024-04-09 name: Emory University class: OTHER briefSummary: The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are:
* whether releasing the pectoralis minor prophylactically could have higher final Patient Reported Outcome Measurements (PROMs) Participants will be randomized to either undergo RSA with pectoralis minor release or RSA without pectoralis minor release. conditions: Reverse Total Shoulder Arthroplasty conditions: Rotator Cuff Tear Arthropathy conditions: Advanced Glenohumeral Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Electronic random number generator Single-blinded (concealed to the study participant only, Investigator blinded not feasible) whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Pectoralis Minor Release name: RSA measure: Visual analog Scale (VAS) pain scores measure: Visual analog Scale (VAS) pain scores measure: American Shoulder and Elbow Score (ASES) measure: Subjective Shoulder Value (SSV) measure: Change in Range of motion (ROM) measure: Change in Scapulohumeral Rhythm (SHR) on Digital Dynamic Radiography (DDR) measure: Number of complications measure: Number of reoperations sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emory Clinic city: Atlanta state: Georgia zip: 30322 country: United States name: Eric Wagner, MD role: CONTACT phone: 404-778-7249 email: eric.r.wagner@emory.edu name: Musab Gulzar role: CONTACT phone: 201-344-0298 email: mgulzar@emory.edu name: Michael Gottschalk, MD role: SUB_INVESTIGATOR lat: 33.749 lon: -84.38798 facility: Emory Healthcare Orthopaedics and Spine Center city: Atlanta state: Georgia zip: 30329 country: United States name: Eric Wagner, MD role: CONTACT phone: 404-778-7249 email: Eric.r.wagner@emory.edu name: Musab Gulzar role: CONTACT phone: 201-344-0298 email: mgulzar@emory.edu lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06292156 id: CASPsy7 briefTitle: tACS Treatment for Cognitive Impairments in Methamphetamine Addicts overallStatus: RECRUITING date: 2023-02-20 date: 2024-08 date: 2024-08 date: 2024-03-04 date: 2024-03-04 name: Beijing HuiLongGuan Hospital class: OTHER briefSummary: 1. To evaluate the cognitive function of methamphetamine Patients.
3. The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients conditions: Methamphetamine Abuse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Theta treatment group name: Alpha active control group name: Sham control group measure: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) measure: ERP components associated with cognitive function measure: Condition stop signal task measure: Neural oscillations associated with cognitive function measure: Functional connection of brain region associated with cognitive function measure: Microstate associated with cognitive function measure: The effect of oxidative stress system on cognitive function measure: The effect of immune system on cognitive function measure: The effect of brain derived neurotrophic factor(BDNF) on cognitive function measure: Genetic mechanism of cognitive function measure: Reverse learning task measure: Beck Depression Scale measure: Barrett impulse Scale measure: Degree of insomnia measure: The Sensitivity to Punishment and Reward Questionnaire measure: Visual analog scale measure: The Desires for Drug Questionnaire measure: Obsessive compulsive drug use scale measure: Obsessive-compulsive inventory measure: Thought Control Ability Questionnaire measure: Thought Suppression Questionnaire measure: Rumination Questionnaire measure: Anger Rumination Questionnaire measure: Beck Anxiety Scale measure: Emotional Regulation Difficulty Scale measure: Aggressive questionnair sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Xin Hua Drug Rehabilitation Center status: RECRUITING city: Mianyang country: China name: China role: CONTACT lat: 31.46784 lon: 104.68168 hasResults: False
nctId: NCT06292143 id: EU101136769-CLIN2 briefTitle: AI4HOPE Dementia Care Planning Pilot Study 2 ( AI4HOPE2) acronym: AI4HOPE-P2 overallStatus: NOT_YET_RECRUITING date: 2025-07 date: 2026-12 date: 2026-12 date: 2024-03-04 date: 2024-03-04 name: University of Bonn class: OTHER name: University College Cork name: University of Leeds name: Fundacion Intras name: Universidade do Porto name: University Medical Centre Maribor briefSummary: This pilot study will test a digital care planning decision support system for patients with dementia. conditions: Dementia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Feasibility study primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 150 type: ESTIMATED name: Advance Care Planning Toolkit measure: Ease of use of digital platform measure: Effect of digital platform on documentation of advance care planning sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Bonn city: Bonn zip: 53127 country: Germany lat: 50.73438 lon: 7.09549 hasResults: False
nctId: NCT06292130 id: 156588-01 briefTitle: Health-Kit Enabled Mobile App for Tobacco Cessation overallStatus: COMPLETED date: 2022-03-21 date: 2023-09-21 date: 2023-09-21 date: 2024-03-04 date: 2024-03-04 name: Pro-Change Behavior Systems class: OTHER briefSummary: Tobacco use remains the leading preventable cause of death in the US, contributing to more than 480,000 premature deaths each year. The Tobacco Treatment Guidelines underscore the need to offer patients who use tobacco products brief interventions that include prescriptions for proven pharmacological smoking cessation aids and proactive connections to evidence-based behavioral support. The rapid expansion of smart phone capabilities enhances the potential for tobacco cessation apps to personalize behavior change guidance and to send contextually relevant tailored behavior change nudges based on readiness to quit and electronic heath record (EHR) data. Rich data from EHRs are now available to third-party apps from the Health app (iOS) via Fast Healthcare Interoperability Resources standard Application Programming Interface (API).
This Phase I SBIR will explore the acceptability and effects of one such innovative health IT solution. Refresh is a highly individualized tobacco cessation HealthKit enabled app that will 1) implement a full range of best practices in tailored health behavior change communications based on readiness to change; 2) individualize behavior change guidance based on Health app data; and 3) concisely provide data and documentation of key actionable insights in the EHR on the patient's smoking status, app usage, and brief micro-message clinicians can deliver to reinforce and accelerate a patient's behavior change progress. This interoperability will provide value to both patients and clinicians; empower and support successful and lasting behavior change; and enable the implementation and evaluation of a best-in-class approach to tobacco and nicotine treatment.
Extensive end user and stakeholder input will ensure refresh is designed for rapid dissemination. Patients of an integrated delivery system with an upcoming appointment (n=100) will be recruited to participate in a 30-day pilot test. Pilot participants will provide quantitative and qualitative data, and utilization and acceptability data will be examined. Pre-post comparisons of PROMIS measure for tobacco (psychosocial expectancies) will provide preliminary data on the effects of the program. Acceptability data from participating clinicians (n=10) who receive and deliver EHR prompts will also be gathered. The hypothesis is that the patients who utilize refresh will have significantly higher psychosocial expectancies regarding tobacco at follow-up. Secondary outcomes will be examined. conditions: Cigarette Smoking studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single group, repeated measures (2 timepoints) primaryPurpose: TREATMENT masking: NONE count: 51 type: ACTUAL name: refresh measure: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome measure: Confidence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pro-Change Behavior Systems, Inc city: South Kingstown state: Rhode Island zip: 02879 country: United States lat: 41.44718 lon: -71.52494 hasResults: False
nctId: NCT06292117 id: 230247 briefTitle: Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke acronym: ORCA-AIS overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-06 date: 2026-06 date: 2024-03-04 date: 2024-03-04 name: University of Virginia class: OTHER name: American Heart Association briefSummary: The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood thinners to prevent it from happening again. One of these blood thinners, called clopidogrel, is less effective in some people due to differences in their DNA. Clopidogrel needs to be activated by a specific enzyme in the body known as CYP2C19. This enzyme does not work as well if there are variations in the section of DNA that tells the body how to make CYP2C19. It can be predicted who has less CYP2C19 enzyme activity with a genetic test. If these patients are given a different blood thinner, it can reduce their risk of another stroke compared to if they are given clopidogrel.
Participants in this study will have a genetic test done onsite looking for variations in the section of DNA that tells the body how to make CYP2C19. This genetic test will only look for 11 known variations; the genome will not be sequenced. The investigators will alert the doctor of the patient's test results so they can prescribe the appropriate blood thinner. Through this, the investigators will learn the best practices for successful implementation of this genetic test. conditions: Ischemic Stroke conditions: CYP2C19 Polymorphism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 350 type: ESTIMATED name: CYP2C19 Genotype measure: Percentage of patients discharged from University of Virginia (UVA) Health on dual antiplatelet therapy with a diagnosis of AIS/TIA meeting eligibility criteria upon presentation that are successfully genotyped measure: Average turnaround time of genotype result from time of collection of blood sample to time result is entered into the electronic health record measure: Number of CYP2C19 LOF carriers for whom a genotype-guided modification to DAPT is made measure: Number needed to genotype (NNG): number of patients who would need to undergo genotyping to have a recommended change in DAPT based on genotype measure: Stroke-free status via the Questionnaire to Verify Stroke-Free Status (QVSFS) of participants at 90 days in participants who received DAPT measure: Major adverse cardiovascular events at 90 days in participants who received DAPT measure: Correlation between P2Y12 reaction units (PRUs) measured via P2Y12 assay and CYP2C19 genotype in patients who received DAPT measure: Acceptability of deferred consent process in participants approached for full informed consent measure: Cost-effectiveness of CYP2C19-guided dual antiplatelet therapy after acute ischemic stroke sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06292104 id: STU-2023-0589 id: 1R01HL166272-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R01HL166272-01A1 briefTitle: Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS) overallStatus: RECRUITING date: 2024-03-05 date: 2028-12 date: 2029-01 date: 2024-03-04 date: 2024-04-26 name: University of Texas Southwestern Medical Center class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities. conditions: Postural Orthostatic Tachycardia Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 350 type: ESTIMATED name: multimodal diagnostic testing measure: Phenotyping POTS measure: Natural history measure: Natural history sex: ALL minimumAge: 14 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: UT Southwestern Medical Center status: RECRUITING city: Dallas state: Texas zip: 75208 country: United States name: Steven Hopkins role: CONTACT phone: 214-648-9275 email: steve.hopkins@utsouthwestern.edu name: Steven Hopkins role: CONTACT phone: 2146489275 email: steve.hopkins@utsouthwestern.edu name: Steven Vernino, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06292091 id: Ur_ABD_PK briefTitle: A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril overallStatus: COMPLETED date: 2024-02-28 date: 2024-03-27 date: 2024-04-01 date: 2024-03-04 date: 2024-04-17 name: Seoul National University Hospital class: OTHER briefSummary: The aim of this study is to evaluate the effect of urine acid-base disequilibrium on the pharmacokinetics of captopril in healthy male volunteers. conditions: Hypertension studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 12 type: ACTUAL name: Captopril 12.5 Mg name: Sodium bicarbonate 4 G name: Torsemide 20 MG measure: AUClast of captopril measure: Cmax of captopril measure: AUCinf of captopril measure: Tmax of captopril measure: t1/2 of captopril measure: CL/F of captopril measure: Vd/F of captopril measure: fe of captopril measure: urine pH measure: Safety parameters sex: MALE minimumAge: 19 Years maximumAge: 50 Years stdAges: ADULT facility: Seoul National University Hospital city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06292078 id: 1R01DA059401-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA059401-01 id: 1R01DA059401-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA059401-01 briefTitle: Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA) acronym: ISLA overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-08 date: 2028-08 date: 2024-03-04 date: 2024-03-04 name: University of Oregon class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This project will test the effectiveness of the Inclusive Skill-building Learning Approach (ISLA) in reducing the use of exclusionary discipline, improving teacher practice and student outcomes, and decreasing substance misuse using a randomized controlled trial in 60 middle schools across six states. conditions: Opioid Misuse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 5076 type: ESTIMATED name: Instructional Skill-Building Learning Approach (ISLA) measure: Frequency and Duration of Use of Office Discipline Referrals, In-School Suspension, and Out-of-School Suspension measure: Engagement vs. Disaffection with Learning Student-report measure: Inclusive Teaching Practices measure: School Climate Survey- Student measure: School Climate- Teacher measure: Student-Teacher Relationships measure: Opioid and Other Substance Misuse measure: Student Internalizing Behaviors measure: Student Externalizing Behaviors measure: ISLA Acceptability measure: ISLA Implementation Fidelity sex: ALL minimumAge: 8 Years maximumAge: 15 Years stdAges: CHILD hasResults: False